^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | senaparib (IMP4297) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial
Published date:
06/20/2023
Excerpt:
…BRCAmut+ solid tumors (ovarian, breast, or prostate cancer were preferred…Senaparib was well tolerated, had good PK properties, and showed encouraging signs of antitumor activity in Chinese patients with previously treated, advanced solid tumors, as well as in a subpopulation of patients harboring BRCAmut+.
DOI:
10.1093/oncolo/oyad163
Trial ID:
